MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-07-2022
AVEO Pharmaceuticals Total Non Current Liabilities 2011-2026 | AVEO
Annual Total Non Current Liabilities AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 14.7 M | 14.6 M | 37 M | 58.8 M | 18.9 M | 10.9 M | 9.7 M | 45 M | 49.4 M | 36.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58.8 M | 9.7 M | 29.6 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M |  USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
AbCellera Biologics
ABCL
|
326 M | $ 3.63 | - | $ 1.08 B |  Canada |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
ADMA Biologics
ADMA
|
99.5 M | $ 16.54 | - | $ 3.94 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
289 M | $ 19.86 | - | $ 2.51 B | USA |
 |
Aptorum Group Limited
APM
|
2.21 M | $ 0.83 | - | $ 4.53 M | China |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Cabaletta Bio
CABA
|
43.9 M | $ 3.43 | 5.54 % | $ 4.01 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
182 M | $ 76.53 | - | $ 1.48 B | USA |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Athersys
ATHX
|
5.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
648 K | $ 24.69 | - | $ 3.02 B | USA |
 |
Citius Pharmaceuticals
CTXR
|
6.01 M | $ 0.82 | - | $ 5.52 M | USA |
 |
Axsome Therapeutics
AXSM
|
48.9 M | $ 164.08 | - | $ 8.16 B | USA |
 |
Champions Oncology
CSBR
|
1 M | $ 6.0 | - | $ 82 M | USA |
 |
BridgeBio Pharma
BBIO
|
97.6 M | $ 66.54 | - | $ 12.7 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | USA |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Equillium
EQ
|
8.33 M | $ 1.75 | -1.13 % | $ 60.8 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
48 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | USA |
 |
Eton Pharmaceuticals
ETON
|
4.56 M | $ 17.53 | - | $ 450 M | USA |
 |
Evogene Ltd.
EVGN
|
5.36 M | $ 0.84 | - | $ 27.9 M |  Israel |
 |
Exelixis
EXEL
|
63.6 M | $ 41.69 | - | $ 11.3 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
8.22 M | $ 2.81 | - | $ 908 M | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
635 M | $ 60.43 | - | $ 11.6 B | USA |